Researchers at Beth Israel Deaconess Medical Center of the Harvard Medical School in Boston, Massachusetts, have developed a contrast agent which makes visible the microcalcifications in malignant breast tumors.  The agent, which absorbs light in the near infrared spectrum, is attached to a pamidronate derivative allowing researchers to synthesize large amounts of their new contrast agent called Pam800.

Researchers are currently running trials on pigs to see how well the agent will make visible, under an infrared (IR) camera, malignant abnormal tissue.

To read more about this article click on the link below:

New near-infrared contrast agent reveals bone and breast-cancer-related microcalcifications